Eli Lilly (LLY) Stock: Company Acquires Merida Biosciences in $2.88 Billion Autoimmune Deal
TLDR
- Eli Lilly is acquiring privately held Merida Biosciences for up to $2.88 billion in cash.
- The deal gives Lilly rights to MER511, an early-stage drug targeting Graves’ disease and thyroid eye disease.
- Merida’s pipeline also includes MER769, targeting food allergy, asthma, and other allergic conditions.
- The acquisition follows Lilly’s $2.4 billion purchase of Orna Therapeutics earlier in 2026.
- LLY stock slipped 0.3% in premarket trading Monday following the announcement.
Eli Lilly announced Monday it will acquire privately held Merida Biosciences for up to $2.88 billion in cash. The deal includes an upfront payment plus contingent milestone payments, with the transaction expected to close in Q4 2026.
LLY stock dipped 0.3% in premarket trading on the news.
Merida is developing biologic drugs that selectively target harmful antibodies linked to autoimmune and allergic conditions. Its lead candidate, MER511, is in early clinical development for Graves’ disease and thyroid eye disease.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
